Clinical trials: Neoplasms, Oral
Solid Tumor
The Intersection of Oncology Care and Worker Well-Being
The goals of this study will be a greater understanding of cancer patients' well-being experience through the care/treatment continuum.
- Trial name
- NCT05250284
- Testing
- WellBQ, PROMIS
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Colorado, Denver
Lung Cancer
Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00004055
- Testing
- filgrastim, paclitaxel, topotecan hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 38 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Atrial Fibrillation
Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy
- Trial name
- MAFIC (NCT04508855)
- Testing
- Low molecular weight heparin
- Where
- 2 sites in Greece
- Sponsor
- AHEPA University Hospital
Oral Cavity Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction
- Trial name
- NeoNivo (NCT03843515)
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Amsterdam UMC, location VUmc
Acute Myeloid Leukemia
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
To find a recommended dose of ASTX727 (cedazuridine/decitabine) in combination with venetoclax for pediatric patients with relapsed AML.
- Trial name
- NCT06191978
- Testing
- ASTX727, Venetoclax
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Potentially Malignant Disorder, Oral Cancer
The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
The mortality rate of oral cancer in Taiwan is still high with no decrease. One of the reasons result in these situations is the patent visits hospital for treatment in late stage of oral cancer.
- Conditions
- Oral Potentially Malignant Disorder, Oral Cancer, Malignant Disorder, p62/SQSTM1
- Trial name
- p62/SQSTM1 (NCT01946230)
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Solid Tumor, Adult, Oncology
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors.
- Trial name
- NCT05055609
- Testing
- TRE-515
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Trethera
Neoplasms, Arteriovenous Malformation of Central Nervous System
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time…
- Conditions
- Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
- Trial name
- NCT01885299
- Testing
- SRS/SBRT
- Where
- 13 sites in United States
- Volunteers
- 50,000 people
- Sponsor
- The Radiosurgery Society
Cancer
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
The study is a Phase 1, open-label study designed to characterize the absorption, distribution, metabolism and excretion of GSK2118436 following administration of a single oral 14C labeled dose of GSK2118436 as a suspension in…
- Trial name
- NCT01262963
- Testing
- GSK2118436
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Head and Neck Cancer
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898664
- Testing
- cytogenetic analysis, gene expression analysis, mutation analysis
- Volunteers
- 74 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Solid Tumor, Metastatic Solid Tumor
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
- Trial name
- NCT06577987
- Testing
- CID-078 Monotherapy
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- Circle Pharma
Oral Mucositis, Head and Neck Neoplasms
Ozone Therapy for the Treatment of Oral Mucositis in Patients Undergoing Radio and Chemotherapy in the Head and Neck Region
The present study aims to evaluate the effectiveness of a combined protocol of professional and at-home ozone therapy in the treatment of oral mucositis in patients undergoing radio- and/or chemotherapy.
- Trial name
- NCT07247799
- Testing
- Ozone treatment
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Andrea Scribante
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-FLEX (NCT07807163)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bicara Therapeutics
Hematologic Malignancy, Acute Lymphocytic Leukemia
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
This is an open-label, single arm study. Approximately 3-30 patients will be enrolled. Patients will receive Oral ciclopirox olamine (aqueous suspension), initial starting dose of 5 mg/m2/day administered as a single dose daily…
- Conditions
- Hematologic Malignancy, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia
- Trial name
- NCT00990587
- Testing
- Ciclopirox Olamine
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Oral Cancer
Oral Pathology Asynchronous Telementoring Pilot Study
The purpose of the proposed research project is to evaluate and enhance the feasibility and acceptability of integrating a tele-mentoring component into the identification of oral lesions at the 6 dental clinics of Family Health…
- Trial name
- NCT04166214
- Testing
- Imaging using intraoral cameras
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Metastatic Pancreatic Cancer
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and…
- Trial name
- NCT05586516
- Testing
- IOA-289
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 16 people
- Sponsor
- iOnctura
Pancreas Neoplasms
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas.
- Trial name
- DOVIPA (NCT06757244)
- Testing
- Dostarlimab, Vitamin D3 (Cholecalciferol), mFOLFIRINOX Treatment Regimen
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- Hopital Foch
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.